Caplacizumab and Breastfeeding

Summary of use during lactation

No information is available on the clinical use of caplacizumab during breastfeeding. Because caplacizumab is a large protein molecule with a molecular weight of about 28,000 Da, the amount in milk is likely to be extremely low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Use of the drug after 2 weeks postpartum may minimize transfer to the infant.[1] Until more data become available, caplacizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Some opinion recommends that patients with acquired thrombotic thrombocytopenic purpura not breastfeed because anti-platelet sIgA might be present in milk and may adversely affect the infant.[2]

Drug levels in milk and infant serum

Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

Relevant published information was not found as of the revision date.

References

1. Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023;22:350-66.36931808 PubMed
2. Alijotas-Reig J. Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain. Thromb Res 2017;156:195-7.28697902 PubMed